Jan van Riggelen

2.3k total citations · 1 hit paper
20 papers, 1.7k citations indexed

About

Jan van Riggelen is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Jan van Riggelen has authored 20 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Immunology. Recurrent topics in Jan van Riggelen's work include Epigenetics and DNA Methylation (4 papers), RNA modifications and cancer (4 papers) and Cancer-related Molecular Pathways (4 papers). Jan van Riggelen is often cited by papers focused on Epigenetics and DNA Methylation (4 papers), RNA modifications and cancer (4 papers) and Cancer-related Molecular Pathways (4 papers). Jan van Riggelen collaborates with scholars based in United States, Germany and Georgia. Jan van Riggelen's co-authors include Dean W. Felsher, Alper Yetil, Candace J. Poole, Pavan Bachireddy, Alice C. Fan, Peter S. Choi, Sandra Ryeom, Judah Folkman, Matthew J. Rioth and Emmanuelle Passegué and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Genes & Development.

In The Last Decade

Jan van Riggelen

20 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MYC as a regulator of ribosome biogenesis and protein synthesis

2010 689 citations Jan van Riggelen, Alper Yetil et al. Nature reviews. Cancer profile →

Peers

Countries citing papers authored by Jan van Riggelen

Since Specialization

Citations

This map shows the geographic impact of Jan van Riggelen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan van Riggelen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan van Riggelen more than expected).

Fields of papers citing papers by Jan van Riggelen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan van Riggelen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan van Riggelen. The network helps show where Jan van Riggelen may publish in the future.

Co-authorship network of co-authors of Jan van Riggelen

This figure shows the co-authorship network connecting the top 25 collaborators of Jan van Riggelen. A scholar is included among the top collaborators of Jan van Riggelen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan van Riggelen. Jan van Riggelen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Expression regulation and function of PD-1 and PD-L1 in T lymphoma cells 2021 ·Cellular Immunology ·(unknown), John D. Klement, (unknown), Jan van Riggelen, Kebin Liu	7
2	MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL 2019 ·Epigenetics & Chromatin ·Candace J. Poole, (unknown), Jeong‐Hyeon Choi, Jan van Riggelen	27
3	Indispensable role of the Ubiquitin-fold modifier 1-specific E3 ligase in maintaining intestinal homeostasis and controlling gut inflammation 2019 ·Cell Discovery ·Yafei Cai, Guangxun Zhu, Siyang Liu, Zezheng Pan, (unknown), Candace J. Poole, Chunwan Lu, Huabin Zhu, Bianca N. Islam, Jan van Riggelen, Darren D. Browning, Kebin Liu, Richard S. Blumberg, Nagendra Singh, Honglin Li	59
4	Glycine decarboxylase is a transcriptional target of MYCN required for neuroblastoma cell proliferation and tumorigenicity 2019 ·Oncogene ·Ahmet Alptekin, Bingwei Ye, Yajie Yu, Candace J. Poole, Jan van Riggelen, Yunhong Zha, Han‐Fei Ding	23
5	Targeting the MYC Oncogene in Burkitt Lymphoma through HSP90 Inhibition 2018 ·Cancers ·Candace J. Poole, Wenli Zheng, (unknown), (unknown), (unknown), Ahmed Chadli, Jan van Riggelen	17
6	FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome 2018 ·Leukemia ·Tianxiang Hu, Qing Wu, Yating Chong, Haiyan Qin, Candace J. Poole, Jan van Riggelen, Mingqiang Ren, John K. Cowell	19
7	MYC—Master Regulator of the Cancer Epigenome and Transcriptome 2017 ·Genes ·Candace J. Poole, Jan van Riggelen	103
8	DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt’s lymphoma 2017 ·Oncotarget ·Candace J. Poole, Wenli Zheng, (unknown), Aleksey Yevtodiyenko, (unknown), Honglin Li, Dean W. Felsher, Jan van Riggelen	45
9	p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia 2015 ·Oncotarget ·Alper Yetil, Benedict Anchang, Arvin M. Gouw, Stacey J. Adam, Tahera Zabuawala, Ramya Parameswaran, Jan van Riggelen, Sylvia K. Plevritis, Dean W. Felsher	19
10	High throughput automated chromatin immunoprecipitation as a platform for drug screening and antibody validation 2012 ·Lab on a Chip ·Angela Ruohao Wu, Tiara L.A. Kawahara, Nicole A. Rapicavoli, Jan van Riggelen, Emelyn H. Shroff, Liwen Xu, Dean W. Felsher, Howard Y. Chang, Stephen R. Quake	49
11	Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction 2011 ·Proceedings of the National Academy of Sciences ·Peter S. Choi, Jan van Riggelen, Andrew J. Gentles, Pavan Bachireddy, Kavya Rakhra, Stacey J. Adam, Sylvia K. Plevritis, Dean W. Felsher	29
12	The interaction between Myc and Miz1 is required to antagonize TGFβ-dependent autocrine signaling during lymphoma formation and maintenance 2010 ·Genes & Development ·Jan van Riggelen, Judith M. Müller, Tobias Otto, Vincent Beuger, Alper Yetil, Peter S. Choi, Christian Kosan, Tarik Möröy, Dean W. Felsher, Martin Eilers	94
13	MYC as a regulator of ribosome biogenesis and protein synthesis breakdown → 2010 ·Nature reviews. Cancer ·Jan van Riggelen, Alper Yetil, Dean W. Felsher	689
14	TGFβ-dependent gene expression shows that senescence correlates with abortive differentiation along several lineages in Myc-induced lymphomas 2010 ·Cell Cycle ·Judith M. Müller, Birgit Samans, Jan van Riggelen, Giovanni Fagà, (unknown), Chia‐Lin Wei, Heiko Müller, Bruno Amati, Dean W. Felsher, Martin Eilers	6
15	Myc and a Cdk2 senescence switch 2009 ·Nature Cell Biology ·Jan van Riggelen, Dean W. Felsher	21
16	Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation 2007 ·Proceedings of the National Academy of Sciences ·(unknown), Jan van Riggelen, Alper Yetil, Alice C. Fan, Pavan Bachireddy, Dean W. Felsher	336
17	Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch 2006 ·Proceedings of the National Academy of Sciences ·Sylvie Giuriato, Sandra Ryeom, Alice C. Fan, Pavan Bachireddy, Ryan C. Lynch, Matthew J. Rioth, Jan van Riggelen, (unknown), Emmanuelle Passegué, Flora Tang, Judah Folkman, Dean W. Felsher	115
18	Loss of Net as Repressor Leads to Constitutive Increased c-fos Transcription in Cervical Cancer Cells 2004 ·Journal of Biological Chemistry ·Jan van Riggelen, Gilles Buchwalter, Ubaldo Soto, (unknown), Harald zur Hausen, Bohdan Wasylyk, Frank Rösl	29
19	Ectopic Expression of Nonliganded Retinoic Acid Receptor β Abrogates AP-1 Activity by Selective Degradation of c-Jun in Cervical Carcinoma Cells 2004 ·Journal of Biological Chemistry ·(unknown), Ubaldo Soto, Jan van Riggelen, Elisabeth Schwarz, Harald zur Hausen, Frank Rösl	10
20	Disturbance of Tumor Necrosis Factor Alpha-Mediated Beta Interferon Signaling in Cervical Carcinoma Cells 2002 ·Journal of Virology ·Anastasia Bachmann, (unknown), Rainer Zawatzky, Ubaldo Soto, Jan van Riggelen, Harald zur Hausen, Frank Rösl	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact